Hematological Malignancies research hub
4 indexed studies · 0 currently recruiting
- active not recruitingPHASE1, PHASE2
Study of AZD9829 in CD123+ Hematological Malignancies
This study is testing a new medicine called AZD9829 for people in the UK with certain blood cancers where other treatments haven't worked or stopped working. Researchers want to see if it's safe and effective, given alone or with other treatments, for cancers that have a specific marker called CD123.
United States · Australia · China - active not recruitingPHASE2
A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
This study is testing a new medicine, teclistamab, for people with multiple myeloma that has come back or hasn't responded to other treatments. It's looking at how well the medicine works at a specific dose.
United States · Belgium · Canada - active not recruitingPHASE1, PHASE2
Durvalumab and Tremelimumab for Pediatric Malignancies
This study is testing new drug combinations to treat children and teenagers with advanced cancer. We're looking for the safest and most effective dose of these immunotherapy drugs, durvalumab and tremelimumab, for solid and blood cancers.
United States · France · Germany - authorisedPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2, Multicenter, Open-Label, Multi-Cohort, First-in Human Trial of DS3790a, a DXd-ADC targeting CD37, for Hematological Malignancies.
This study is testing a new medicine called DS3790a for blood cancers. It's an early-stage trial looking at how safe the medicine is, what side effects it might cause, and if it helps people get better. We're also checking how well different ways of giving the medicine work.
France · Italy